In vitro
This study investigated whether the gastric pentadecapeptide BPC-157 and two newly designed hybrid analogs (CIARA-1 and CIARA-2) could inhibit acetylcholinesterase (AChE), an enzyme targeted in the treatment of neurodegenerative conditions such as Alzheimer's disease. The hybrid peptides were rationally designed by combining a BPC-157-derived fragment with an arginine-rich C-terminal sequence intended to enhance binding at both the catalytic and peripheral sites of AChE. Inhibitory activity was measured in vitro using a modified Ellman colorimetric assay, with kinetic parameters derived from Lineweaver-Burk plots. All three compounds showed competitive inhibition—meaning they raised the Michaelis-Menten constant (Km) without affecting maximum velocity (Vmax)—indicating direct competition with the substrate at the enzyme's active site. CIARA-1 showed the strongest inhibition (Ki = 0.24 mM; IC50 = 2.52 mM), followed by CIARA-2 and then BPC-157 itself. Results were supported by molecular docking predictions. A key limitation is that inhibitory potencies were substantially lower than those of approved AChE inhibitors. No animal or human data were included. The authors suggest these peptides represent a structural scaffold for further optimization rather than immediate therapeutic candidates.
International journal of molecular sciences · May 2026DOI ↗ In vitroPreprint
This paper proposes a molecular mechanism for BPC-157, a synthetic 15-amino-acid peptide previously studied in preclinical models for regenerative and cytoprotective effects. The authors hypothesize — based on computational structural modeling and in silico docking — that BPC-157 adopts a polyproline II (PPII) helix conformation and engages the SH3 domains of Src family kinases (c-Src, Yes, Fyn). The proposed interaction is suggested to relieve autoinhibition of these kinases, potentially activating downstream FAK-ERK and PI3K-Akt signaling pathways. To build a tool for future experimental testing, the authors engineered an mCherry-BPC157₂ fusion protein, encoded it in a baculovirus vector, and expressed it in insect (Sf9) cells. Expression was confirmed by fluorescence imaging and western blot at the expected ~31 kDa size. Importantly, this study does not include human subjects, animal experiments, or in vitro binding assays — the core mechanistic claims rest entirely on computational modeling. The fusion protein work is a proof-of-concept for a future experimental reagent. Findings should be interpreted as hypothesis-generating only.
Unknown journal · Dec 2025DOI ↗ In vitroPreprint
This paper proposes a molecular mechanism for BPC-157, a synthetic pentadecapeptide previously studied in preclinical settings for regenerative and cytoprotective properties. The authors use structural modeling and in silico docking to hypothesize that BPC-157 adopts a polyproline II (PPII) helix conformation that enables it to bind the SH3 domains of Src family kinases (SFKs), including c-Src, Yes, and Fyn. According to this model, such binding would relieve SH3-mediated autoinhibition of these kinases, triggering downstream FAK-ERK and PI3K-Akt signaling cascades associated with cell survival and repair. To build a tool for future experimental validation, the researchers engineered an mCherry-BPC157₂ fluorescent fusion protein, encoded it in a baculovirus vector, and expressed it in Sf9 insect cells. Expression was confirmed by fluorescent imaging and western blot at the predicted ~31 kDa molecular weight. Notably, no binding interaction or functional activity in mammalian systems was experimentally demonstrated; the SH3 engagement hypothesis remains computational. Limitations include the absence of human or animal data, reliance on in silico docking, and use of an insect cell expression system solely for protein production validation.
Unknown journal · Nov 2025DOI ↗ In vitro
This study developed and validated a novel analytical strategy for characterizing how BPC-157 — a peptide classified as a doping agent — is metabolized in laboratory (in vitro) conditions. The researchers used stable isotope labeling (¹³C/¹⁵N-labeled BPC-157) combined with ultra-high-performance liquid chromatography–high-resolution mass spectrometry (UHPLC-HRMS) to systematically identify metabolites without needing prior knowledge of metabolic pathways. Using two in vitro incubation models, the study identified nine total metabolites: eight arising from conventional amide-bond cleavage and one from a previously unreported metabolic pathway. The team then developed and validated a detection method for BPC-157 and five key metabolites in human urine, achieving detection limits of 0.01–0.11 ng/mL and strong quantitative performance. Importantly, this was an entirely in vitro study; no human participants or animals were involved, meaning the metabolic profile observed may not fully reflect what occurs in the human body. The findings are primarily relevant to anti-doping laboratories seeking improved detection targets and analytical workflows, and do not speak to the biological effects or clinical utility of BPC-157.
Molecules (Basel, Switzerland) · Oct 2023DOI ↗